Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07736638) titled 'A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants' on July 27.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: AbbVie

Condition: Healthy Volunteer

Intervention: Drug: ABBV-859 Drug: Placebo for ABBV-859 Drug: ABBV-859

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: July 28, 2026

Target Sample Size: 64

To know more, visit https://clinicaltria...